Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.
http://www.priceseries.com/trade/ZYNE-Zynerba-Pharmaceuticals-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2019040220190418.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments